证券日报网讯1月7日，万孚生物（300482）在互动平台回答投资者提问时表示，公司已制定并审议通过 了《市值管理制度》，公司已经系统性推进市值管理各项工作。在具体实践中，公司的市值管理以提升 主营业务竞争力、优化公司治理、持续提升信息披露质量等方式开展。 ...

| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2026-003 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 关于补选公司第五届董事会独立董事和选举非独立董 事并调整董事会专门委员会委员的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 广州万孚生物技术股份有限公司（以下简称"公司"）于 2026 年 1 月 6 日 召开第五届董事会第二十次会议，审议通过了《关于补选王菊芳女士为公司第 五届董事会独立董事的议案》《关于选举汪洋先生为公司第五届董事会非独立董 事的议案》及《关于调整公司董事会专门委员会组成人员的议案》，现将有关情 况公告如下： 一、关于补选公司第五届董事会独立董事的情况 董事会于近日收到独立董事段朝晖先生提交的书面辞职报告，段朝晖先生 因个人工作原因申请辞去公司第五届董事会独立董事职务，同时辞去董事会薪 酬与考核委员会主任委员、董事会战略委员会委员职务，其辞职后将不再担任 公司任何职务。段朝晖先生上述职务原定任期为自第五届董事会选举完成 ...

证券代码：300482 证券简称：万孚生物 公告编号：2026-004 广州万孚生物技术股份有限公司 关于召开 2026 年第二次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 重要提示： 1、本次股东会无增加、变更提案的情况。 2、本次股东会以现场投票和网络投票相结合的表决方式。 3、本次股东会未涉及变更前次股东会决议的情形。 4、中小投资者是指除上市公司董事、高级管理人员以及单独或者合计持有公 司 5%以上股份的股东以外的其他股东 一、召开会议的基本情况 1、股东会届次：2026 年第二次临时股东会 2、股东会的召集人：董事会 7、出席对象： （1）截至 2026 年 1 月 20 日下午深圳证券交易所收市时，在中国证券登记结算有限公司深圳分公 司登记在册的本公司全体股东，上述本公司全体股东均有权出席本次股东会，并可以以书面形式委托代 理人出席和参加表决，该股东代理人不必是本公司股东。 （2）本公司董事和高级管理人员。 （3）本公司聘请的律师及其他相关人员。 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所创业板股票上 ...

| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2026-002 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 第五届董事会第二十次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 三、审议通过《关于调整公司董事会专门委员会组成人员的议案》 广州万孚生物技术股份有限公司（以下简称"公司"或"本公司"）第五届 董事会第二十次会议(以下简称"本次会议")于 2026 年 1 月 6 日下午 15:00 在 公司会议室以现场与通讯相结合的方式召开，因情况紧急，为保证董事会工作 的顺利衔接和平稳运行，本次会议经全体董事一致同意豁免会议通知时限要求， 会议通知于同日以电话、口头等方式送达全体董事。会议应到董事 8 名，实到 8 名，出席会议人数符合《公司法》和《公司章程》规定。会议由公司董事长 王继华女士主持。 经与会董事认真审议，本次会议通过以下议案： 一、审议通过《关于补选王菊芳女士为公司第五届董事会独立董事的议案》 为完善公司治理结构，保证公司董事 ...

Group 1 - Haitai Xinguang, based in Qingdao, specializes in the research, production, and sales of medical endoscope instruments and optical products, being a leading enterprise in the domestic medical endoscope optical field [1][30] - The company has established long-term collaborations with international medical giants such as Karl Storz and Olympus, and its high-definition optical imaging technology supports navigation equipment for neurosurgery [1][30] - By 2026, the market demand for its high-end optical components is expected to further release due to the recovery of the medical device sector and the advancement of brain-computer interface medical applications [1][30] Group 2 - Huqiang Technology, registered in Yichang, focuses on special protective equipment, pharmaceutical packaging, and medical devices, with a strong advantage in public health emergency material supply [2][31] - Its medical protective equipment is applicable in sterile operating environments for brain-computer interface implantation surgeries, enhancing product competitiveness in the medical device sector [2][31] Group 3 - Zhengde Medical, headquartered in Shaoxing, is a leading enterprise in the medical dressing industry, with a product matrix covering medical dressings, infection control, and rehabilitation care [3][32] - The company's surgical infection control products meet the sterile operation requirements for brain-computer interface implantation surgeries, and its rehabilitation products cater to post-operative patient management needs [3][32] - By 2026, the surgical infection control consumables business is expected to see market growth as brain-computer interface medical applications accelerate [3][32] Group 4 - Linuo Pharmaceutical Packaging, based in Jinan, specializes in the research, production, and sales of pharmaceutical packaging materials, including sterile medical device packaging suitable for brain-computer interface components [4][33] - The company is gradually expanding into the high-end medical device packaging market, seizing opportunities in the brain-computer interface industry [4][33] Group 5 - Rendu Biotech, located in Shanghai, focuses on RNA molecular diagnostic technology, with applications in infection detection post-brain-computer interface implantation surgeries [5][34] - The company’s post-operative infection detection reagents are expected to see new demand growth by 2026 as brain-computer interface clinical surgeries are promoted [5][34] Group 6 - Huangshan Capsule, based in Anhui, specializes in the research and production of pharmaceutical hollow capsules, gradually expanding into medical device auxiliary materials [6][36] - The company’s medical capsule carriers can adapt to the encapsulation needs of sustained-release bioelectrodes in brain-computer interface devices [6][36] Group 7 - ST Kelly, headquartered in Suzhou, focuses on medical device research and production, particularly in ultrasound equipment and rehabilitation devices [7][37] - The company’s ultrasound diagnostic equipment can be used for pre-operative brain tissue imaging assessments in brain-computer interface surgeries [7][37] Group 8 - Aotai Biotech, based in Hangzhou, specializes in rapid diagnostic reagents, with its rapid infection detection reagents applicable in brain-computer interface clinical settings [8][38] - The company is developing rapid detection products for post-operative neurological function assessment related to brain-computer interfaces [8][38] Group 9 - Dongfang Ocean, located in Yantai, focuses on marine biological medical materials, with collagen materials applicable as coatings for brain-computer interface electrodes [9][39] - The company is increasing its R&D investment in the medical device sector, particularly in the integration of biological medical materials with brain-computer interface devices by 2026 [9][39] Group 10 - Shuoshi Biotech, based in Taizhou, specializes in nucleic acid detection technology, with products applicable for precise diagnosis of post-operative brain infections in brain-computer interface surgeries [10][40] - The company is exploring detection technologies related to neurotransmitters in brain-computer interfaces, aiming for breakthroughs in neurological disease diagnostics [10][40] Group 11 - Guofa Co., located in Beihai, focuses on pharmaceutical manufacturing and medical device sales, with a distribution network covering Guangxi and surrounding areas [11][41] - The company plans to increase its agency layout for high-end medical devices related to brain-computer interfaces by 2026 [11][41] Group 12 - Nanwei Co., based in Nantong, specializes in medical dressings and hygiene products, with its adhesive dressings suitable for post-operative care in brain-computer interface surgeries [12][42] - The company is enhancing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [12][42] Group 13 - Mingde Biotech, located in Wuhan, is a leading enterprise in the field of rapid diagnostic reagents, with products applicable for monitoring vital signs during brain-computer interface surgeries [13][43] - The company is developing rapid assessment devices for post-operative neurological function related to brain-computer interfaces [13][43] Group 14 - Hualan Co., based in Wuxi, specializes in medical rubber products, with its rubber sealing components applicable in fluid control systems for brain-computer interface devices [14][44] - The company is collaborating with research institutions to develop rubber insulation components for brain-computer interface electrodes [14][44] Group 15 - Yuyue Medical, headquartered in Danyang, is a leading enterprise in home medical devices, with products applicable in brain-computer interface surgeries [15][45] - The company is increasing its R&D on medical-grade rehabilitation robots, aiming to integrate brain-computer interface technology with rehabilitation devices [15][45] Group 16 - Shengxiang Biotech, located in Changsha, focuses on nucleic acid detection technology, with products applicable for rapid diagnosis of central nervous system infections post-brain-computer interface surgeries [16][46] - The company is exploring gene detection technologies related to neurological genetic diseases, expanding the application boundaries of molecular diagnostics [16][46] Group 17 - Jiga Development, based in Jinan, focuses on high-end medical device incubation and industrialization, particularly in brain-computer interface-related medical device enterprises [17][47] - The company is responsible for industrial park construction and resource integration for brain-computer interface medical device companies [17][47] Group 18 - Anxu Biotech, located in Hangzhou, specializes in rapid diagnostic reagents, with products applicable for instant infection screening during brain-computer interface surgeries [18][48] - The company is developing rapid detection products for neurotransmitters related to brain-computer interfaces, aiming for breakthroughs in neurological function assessment [18][48] Group 19 - Wantai Biotech, based in Beijing, is a comprehensive enterprise in biopharmaceuticals and medical devices, with products applicable for biochemical index detection post-brain-computer interface surgeries [19][49] - The company is exploring biopharmaceutical development related to brain-computer interfaces, seeking new growth points in nerve repair [19][49] Group 20 - Jiuan Medical, located in Tianjin, focuses on home health devices, with products applicable for synchronized monitoring of brain signals and vital signs in brain-computer interface scenarios [20][50] - The company is increasing its R&D investment in brain-computer interface wearable devices, aiming to create an intelligent medical ecosystem [20][50] Group 21 - Jidan Biotech, based in Nanjing, specializes in POCT reagents and instruments, with products applicable for cardiovascular function assessment in brain-computer interface surgeries [21][51] - The company is developing rapid detection products for post-operative cerebrovascular diseases related to brain-computer interfaces [21][51] Group 22 - Wanfeng Biotech, located in Guangzhou, is a leading enterprise in the POCT field, with products applicable for instant infection screening during brain-computer interface surgeries [22][52] - The company is developing neurobiomarker detection reagents to assess post-operative neurological function recovery, providing comprehensive support for brain-computer interface surgeries [22][52] Group 23 - Haier Biotech, based in Qingdao, specializes in low-temperature storage devices for biological materials, with applications in brain-computer interface-related biological sample preservation [23][53] - The company is increasing its R&D on high-end medical storage devices tailored for brain-computer interface biological materials by 2026 [23][53] Group 24 - Haooubo, located in Suzhou, focuses on immune diagnostic reagents and instruments, with products applicable for immune function assessment in brain-computer interface surgeries [24][54] - The company is developing detection reagents for immune rejection post-brain-computer interface implantation, providing technical support for surgical complications [24][54] Group 25 - Shandong Pharmaceutical Glass, based in Zibo, is a leading enterprise in pharmaceutical glass, with products applicable for insulation packaging of brain-computer interface electrodes [25][55] - The company is expanding into the high-end medical device glass materials market, targeting the brain-computer interface industry [25][55] Group 26 - Innotech, located in Langfang, specializes in infectious disease diagnostic reagents, with products applicable for pre-operative lung infection screening in brain-computer interface surgeries [26][56] - The company is developing rapid detection products for post-operative lung infections related to brain-computer interfaces, aiming for breakthroughs in post-operative complication detection [26][56] Group 27 - Jianer Kang, based in Changzhou, focuses on medical dressings and rehabilitation care products, with its antibacterial medical dressings applicable for post-operative care in brain-computer interface surgeries [27][59] - The company is increasing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [27][59]

Group 1 - The fentanyl concept index rose by 4.74%, ranking 6th among concept sectors, with 8 stocks increasing in value, including Botao Bio which hit a 20% limit up [1] - The leading stocks in the fentanyl sector included Dongfang Bio, Lingrui Pharmaceutical, and ST Renfu, which rose by 5.12%, 4.88%, and 2.26% respectively [1] Group 2 - The fentanyl concept sector saw a net inflow of 55 million yuan, with ST Renfu leading the inflow at 69.89 million yuan, followed by Guoyao Shares, Guoyao Modern, and Lingrui Pharmaceutical [2] - The net inflow ratios for ST Renfu, Guoyao Modern, and Guoyao Shares were 14.70%, 7.69%, and 5.96% respectively, indicating strong interest from major funds [3]

| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2026-001 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 关于 2025 年第四季度可转换公司债券转股情况的公告 （一）可转债发行上市基本情况 经中国证券监督管理委员会"证监许可[2020]1830 号"文同意注册的批复，公 司于 2020 年 9 月 1 日向不特定对象发行了 600 万张可转换公司债券，每张面值 100 元，发行总额 6.00 亿元。 经深交所同意，公司 6.00 亿元可转换公司债券将于 2020 年 9 月 23 日起在 深交所挂牌交易，债券简称"万孚转债"，债券代码"123064"。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： | 证券代码：300482 | | 证券简称：万孚生物 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 债券代码：123064 | | 债券简称 ...

Core Viewpoint - The company announced the resignation of Vice President Kang Keren due to internal governance structure adjustments, but she will continue to serve in another capacity within the company [1][5]. Group 1: Management Changes - Kang Keren submitted a written resignation report to resign from her position as Vice President of the fifth board of directors [1][5]. - After her resignation, Kang Keren was elected as a representative director by the employee representative assembly, with her term lasting until the end of the current board's term [4][8]. Group 2: Background Information - Kang Keren, born in December 1976, holds a doctoral degree and is a senior engineer. She has been with the company in various roles since 2012 [4][8]. - As of the announcement date, Kang Keren holds 175,000 shares in the company, and her salary for 2024 is reported to be 1.0064 million yuan, a decrease of 326,400 yuan compared to 2023 [4][8]. Group 3: Financial Performance - For the first three quarters of 2025, the company reported a revenue of 1.690 billion yuan and a net profit attributable to shareholders of 134 million yuan [9].

格隆汇12月29日丨万孚生物(300482.SZ)公布，公司董事、高级管理人员彭仲雄先生计划以集中竞价的 方式减持公司股份合计不超过29,700股（不超过公司剔除回购专用账户股份数量总股本的0.0064%）。 减持期间为本减持计划公告之日起十五个交易日后的3个月内（2026年1月22日至2026年4月21日）。窗 口期不减持。 ...

Group 1 - Wanfu Convertible Bond proposes a down adjustment [1] - Hongtu Convertible Bond adjusts but does not lower the adjustment period [1] - Oulutong's controlling shareholder plans to reduce holdings by no more than 1.91% of the company's shares [1] - Unisplendour plans to acquire shares of Ruineng Semiconductor, leading to a stock suspension [1] Group 2 - Hongchuan Convertible Bond announced a down adjustment [2] - Hongtu Convertible Bond will not lower the adjustment period [2] - Wanfu Convertible Bond proposes a down adjustment [2] - Baolai Convertible Bond will not undergo a down adjustment [2] Group 3 - Various convertible bonds listed with current prices, redemption prices, last trading dates, last conversion dates, conversion values, remaining scales, and the proportion of convertible bonds to underlying stocks [4][6] - For example, Yingbo Convertible Bond has a current price of 142.440, a redemption price of 100.100, and a conversion value of 142.56 with a remaining scale of 1.103 billion [4] - Liuyao Convertible Bond has a current price of 107.862, a redemption price of 108.000, and a conversion value of 83.85 with a remaining scale of 8.017 billion [6] Group 4 - Quick query highlights include Hongchuan Convertible Bond's adjustment not reaching the bottom and Baolai Convertible Bond not undergoing a down adjustment [8]